FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2904081427> ?p ?o ?g. }

• W2904081427 endingPage "34" @default.
• W2904081427 startingPage "34" @default.
• W2904081427 abstract "Introduction Lutathera® [ [1] Novartis Media Relations. Advanced Accelerator Applications Receives FDA Approval for Lutathera® for Treatment of Gastroenteropancreatic Neuroendocrine Tumors. 1–9 (2018). Available at: https://www.novartis.com/news/media-releases. (Accessed: 6th April 2018) Google Scholar ] have been used to treat patients with neuroendocrine tumors. At the Cancer Research Institute of Montpellier the first patients were treated during 2016. Two software available on the market can be used to compare organ-based absorbed doses, the new version of OLINDA/EXM(OLINDA) V2 [ [2] Stabin, M. & Farmer, A. OLINDA/EXM 2.0: The new generation dosimetry modeling code. J. Nucl. Med. 53, 585 (2012). Google Scholar ] within HERMES workstation and PLANET®Dose (PDose) from DOSISOFT. The goal of this work is to compare organ-based absorbed dose estimations by using the local energy deposit approach (LEDA). Methods One female who benefited from Lutathera® was injected with a total activity of 7176.6 MBq [ 177 Lu-[DOTA0,Tyr3]-octreotate. Four SPECT/CT’s were performed using the GE-Discovery NM/CT 670 at 4 h, 24 h, 72 h and 168 h. Dosmetric comparison was for liver, spleen, left and right kidneys. Segmentation and registration were carried on using PDose. Segmentation using the first CT image has been done organ by organ. Rigid registration was performed for each organ using two SPECT/CT’s series and taking the first SPECT/CT as reference. The volume of reference was the same at all time for this dosimetric study and it was used to estimate the mass. PDose provides a bio-kinetics’ analysis tools in which SPECT/CT calibration factors can be entered; bi-exponential fitting was chosen to estimate cumulated activities. Residence times were computed and entered into OLINDA in order to calculate beta-absorbed dose. On the other hand, PDose can establish the absorbed dose by LEDA choosing a bi-exponential fitting function and correcting for tissue density. To allow comparison with OLINDA, the absorbed dose to kidneys was performed weighting the left/right results by the mass. Results Liver, spleen, left and right kidney mass were 1636 g, 99 g, 145 g and 126 g, respectively. Residence times for liver, spleen, left and right kidney were 42.70 h, 0.62 h, 0.78 h, 0.82 h. For liver, spleen and kidneys absorbed dose estimations are 16.0 Gy, 3.9 Gy, 3.7 Gy for PDose and 16.8 Gy, 3.6 Gy, 3.5 Gy for OLINDA, respectively. Relative difference is −4.8%, 8.9% and 5.2% for the same organs. Using OLINDA other organs such as adrenals glands, lungs and pancreas also register absorbed doses. Conclusions Results obtained with PDose using the LEDA hypothesis (with density correction), weighting by the mass, are consistent with OLINDA (with mass correction) in ± 10% for a selected group of organs. This preliminary study should be continued on other organs/tissues of interest in radionuclide therapy. Lutathera® [ [1] Novartis Media Relations. Advanced Accelerator Applications Receives FDA Approval for Lutathera® for Treatment of Gastroenteropancreatic Neuroendocrine Tumors. 1–9 (2018). Available at: https://www.novartis.com/news/media-releases. (Accessed: 6th April 2018) Google Scholar ] have been used to treat patients with neuroendocrine tumors. At the Cancer Research Institute of Montpellier the first patients were treated during 2016. Two software available on the market can be used to compare organ-based absorbed doses, the new version of OLINDA/EXM(OLINDA) V2 [ [2] Stabin, M. & Farmer, A. OLINDA/EXM 2.0: The new generation dosimetry modeling code. J. Nucl. Med. 53, 585 (2012). Google Scholar ] within HERMES workstation and PLANET®Dose (PDose) from DOSISOFT. The goal of this work is to compare organ-based absorbed dose estimations by using the local energy deposit approach (LEDA). One female who benefited from Lutathera® was injected with a total activity of 7176.6 MBq [ 177 Lu-[DOTA0,Tyr3]-octreotate. Four SPECT/CT’s were performed using the GE-Discovery NM/CT 670 at 4 h, 24 h, 72 h and 168 h. Dosmetric comparison was for liver, spleen, left and right kidneys. Segmentation and registration were carried on using PDose. Segmentation using the first CT image has been done organ by organ. Rigid registration was performed for each organ using two SPECT/CT’s series and taking the first SPECT/CT as reference. The volume of reference was the same at all time for this dosimetric study and it was used to estimate the mass. PDose provides a bio-kinetics’ analysis tools in which SPECT/CT calibration factors can be entered; bi-exponential fitting was chosen to estimate cumulated activities. Residence times were computed and entered into OLINDA in order to calculate beta-absorbed dose. On the other hand, PDose can establish the absorbed dose by LEDA choosing a bi-exponential fitting function and correcting for tissue density. To allow comparison with OLINDA, the absorbed dose to kidneys was performed weighting the left/right results by the mass. Liver, spleen, left and right kidney mass were 1636 g, 99 g, 145 g and 126 g, respectively. Residence times for liver, spleen, left and right kidney were 42.70 h, 0.62 h, 0.78 h, 0.82 h. For liver, spleen and kidneys absorbed dose estimations are 16.0 Gy, 3.9 Gy, 3.7 Gy for PDose and 16.8 Gy, 3.6 Gy, 3.5 Gy for OLINDA, respectively. Relative difference is −4.8%, 8.9% and 5.2% for the same organs. Using OLINDA other organs such as adrenals glands, lungs and pancreas also register absorbed doses. Results obtained with PDose using the LEDA hypothesis (with density correction), weighting by the mass, are consistent with OLINDA (with mass correction) in ± 10% for a selected group of organs. This preliminary study should be continued on other organs/tissues of interest in radionuclide therapy." @default.
• W2904081427 created "2018-12-22" @default.
• W2904081427 creator A5004471345 @default.
• W2904081427 creator A5005185910 @default.
• W2904081427 creator A5015934381 @default.
• W2904081427 creator A5018426174 @default.
• W2904081427 creator A5024683005 @default.
• W2904081427 creator A5029181926 @default.
• W2904081427 creator A5068280775 @default.
• W2904081427 creator A5080314267 @default.
• W2904081427 creator A5089237095 @default.
• W2904081427 date "2018-12-01" @default.
• W2904081427 modified "2023-10-01" @default.
• W2904081427 title "60 Comparison of organ-based absorbed doses estimations by using PLANET®Dose and OLINDA/EXM V2.0 in patients with peptide receptor radionuclide therapy (PRRT) treated with Lutathera®" @default.
• W2904081427 doi "https://doi.org/10.1016/j.ejmp.2018.09.073" @default.
• W2904081427 hasPublicationYear "2018" @default.
• W2904081427 type Work @default.
• W2904081427 sameAs 2904081427 @default.
• W2904081427 citedByCount "2" @default.
• W2904081427 countsByYear W29040814272023 @default.
• W2904081427 crossrefType "journal-article" @default.
• W2904081427 hasAuthorship W2904081427A5004471345 @default.
• W2904081427 hasAuthorship W2904081427A5005185910 @default.
• W2904081427 hasAuthorship W2904081427A5015934381 @default.
• W2904081427 hasAuthorship W2904081427A5018426174 @default.
• W2904081427 hasAuthorship W2904081427A5024683005 @default.
• W2904081427 hasAuthorship W2904081427A5029181926 @default.
• W2904081427 hasAuthorship W2904081427A5068280775 @default.
• W2904081427 hasAuthorship W2904081427A5080314267 @default.
• W2904081427 hasAuthorship W2904081427A5089237095 @default.
• W2904081427 hasConcept C126322002 @default.
• W2904081427 hasConcept C126838900 @default.
• W2904081427 hasConcept C149857219 @default.
• W2904081427 hasConcept C151337348 @default.
• W2904081427 hasConcept C19527891 @default.
• W2904081427 hasConcept C2779066768 @default.
• W2904081427 hasConcept C2989005 @default.
• W2904081427 hasConcept C2993559085 @default.
• W2904081427 hasConcept C71924100 @default.
• W2904081427 hasConcept C75088862 @default.
• W2904081427 hasConceptScore W2904081427C126322002 @default.
• W2904081427 hasConceptScore W2904081427C126838900 @default.
• W2904081427 hasConceptScore W2904081427C149857219 @default.
• W2904081427 hasConceptScore W2904081427C151337348 @default.
• W2904081427 hasConceptScore W2904081427C19527891 @default.
• W2904081427 hasConceptScore W2904081427C2779066768 @default.
• W2904081427 hasConceptScore W2904081427C2989005 @default.
• W2904081427 hasConceptScore W2904081427C2993559085 @default.
• W2904081427 hasConceptScore W2904081427C71924100 @default.
• W2904081427 hasConceptScore W2904081427C75088862 @default.
• W2904081427 hasLocation W29040814271 @default.
• W2904081427 hasOpenAccess W2904081427 @default.
• W2904081427 hasPrimaryLocation W29040814271 @default.
• W2904081427 hasRelatedWork W1833439679 @default.
• W2904081427 hasRelatedWork W1981223719 @default.
• W2904081427 hasRelatedWork W1988250226 @default.
• W2904081427 hasRelatedWork W2017183061 @default.
• W2904081427 hasRelatedWork W2754110156 @default.
• W2904081427 hasRelatedWork W2764084485 @default.
• W2904081427 hasRelatedWork W2900733241 @default.
• W2904081427 hasRelatedWork W2904081427 @default.
• W2904081427 hasRelatedWork W3111581306 @default.
• W2904081427 hasRelatedWork W4255937668 @default.
• W2904081427 hasVolume "56" @default.
• W2904081427 isParatext "false" @default.
• W2904081427 isRetracted "false" @default.
• W2904081427 magId "2904081427" @default.
• W2904081427 workType "article" @default.